KOMPAS.com – Candidate coronavirus vaccine that was developed AstraZeneca and the University of Oxford is reportedly very effective.
This was conveyed by the researchers of the vaccine candidate on Monday (23/11/2020), as reported Associated Press.
Candidate the Covid-19 vaccine it reportedly succeeded in preventing coronavirus infection in 70 percent of the volunteers in the final stage of the trial.
Also read: US Will Hold Covid-19 Vaccine in Early December
One of the researchers, Andrew Pollard, said scientists were happy with the results.
The researchers said that if people were given half a dose followed by a full dose, the protective effectiveness against Covid-19 would be about 90 percent.
Meanwhile, quoted from Politico, when people are given two doses in full, the effectiveness drops to 62 percent instead.
Also read: Study Called the Covid-19 Vaccine Made in China Produces a Fast Immune Response
“These findings show that we have an effective vaccine that will save many lives,” he said.
Two other drug manufacturers, Pfizer and Modern, last week also reported promising preliminary results of the final stage trial.
These preliminary findings indicate that the two companies’ Covid-19 vaccine candidates are nearly 95 percent effective.
Also read: Regarding the validity of Pfizer and Moderna’s Coronavirus Vaccine Data, Fauci said …
Meanwhile, quoted from Reuters, Chief Executive of AstraZeneca Pascal Soriot said, the Covid-19 vaccine candidate they developed was effective against Covid-19.
“The efficacy and safety of this vaccine confirms that it will be highly effective against Covid-19 and will have a direct impact on this public health emergency,” Soriot said in a statement.
The results mark a new breakthrough in the fight against a pandemic that has killed nearly 1.4 million people and rocked the global economy.
– .
